Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Richards

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
Gastroenterology|August 25, 2015
Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin StudyRohit Loomba, Nicholas Schork, Chi-Hua Chen, et al.
Hepatology (Baltimore, Md.)|November 7, 2017
Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosisCyrielle Caussy, Mosab H Alquiraish, Phirum Nguyen, et al.
Gut|November 20, 2020
MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosisJinho Jung, Rohan R Loomba, Kento Imajo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 19, 2018
Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic SteatohepatitisRohit Loomba, Anjali Jain, Anna Mae Diehl, et al.
Alimentary Pharmacology & Therapeutics|December 4, 2018
Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLDCyrielle Caussy, Cynthia Hsu, Seema Singh, et al.
Hepatology (Baltimore, Md.)|September 27, 2019
Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver DiseaseVeeral H Ajmera, Amy Liu, Seema Singh, et al.
Therapeutic Advances in Gastroenterology|March 2, 2016
Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trialSteven C Lin, Brandon Ang, Carolyn Hernandez, et al.
Hepatology Communications|May 16, 2025
Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD)Luis Antonio Díaz, Federica Tavaglione, Nikita Mittal, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 5, 2023
Development and Validation of the Nonalcoholic Fatty Liver Disease Familial Risk Score to Detect Advanced Fibrosis: A Prospective, Multicenter StudyDaniel Q Huang, Noora Ahlholm, Panu K Luukkonen, et al.
Hepatology (Baltimore, Md.)|March 25, 2018
Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLDCyrielle Caussy, Cynthia Hsu, Min-Tzu Lo, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Gastroenterology|August 25, 2015
Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin StudyRohit Loomba, Nicholas Schork, Chi-Hua Chen, et al.
Hepatology (Baltimore, Md.)|November 7, 2017
Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosisCyrielle Caussy, Mosab H Alquiraish, Phirum Nguyen, et al.
Gut|November 20, 2020
MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosisJinho Jung, Rohan R Loomba, Kento Imajo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 19, 2018
Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic SteatohepatitisRohit Loomba, Anjali Jain, Anna Mae Diehl, et al.
Alimentary Pharmacology & Therapeutics|December 4, 2018
Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLDCyrielle Caussy, Cynthia Hsu, Seema Singh, et al.
Hepatology (Baltimore, Md.)|September 27, 2019
Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver DiseaseVeeral H Ajmera, Amy Liu, Seema Singh, et al.
Therapeutic Advances in Gastroenterology|March 2, 2016
Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trialSteven C Lin, Brandon Ang, Carolyn Hernandez, et al.
Hepatology Communications|May 16, 2025
Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD)Luis Antonio Díaz, Federica Tavaglione, Nikita Mittal, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 5, 2023
Development and Validation of the Nonalcoholic Fatty Liver Disease Familial Risk Score to Detect Advanced Fibrosis: A Prospective, Multicenter StudyDaniel Q Huang, Noora Ahlholm, Panu K Luukkonen, et al.
Hepatology (Baltimore, Md.)|March 25, 2018
Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLDCyrielle Caussy, Cynthia Hsu, Min-Tzu Lo, et al.
Pageof 8